Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

8.0%

2 terminated/withdrawn out of 25 trials

Success Rate

92.0%

+5.5% vs industry average

Late-Stage Pipeline

16%

4 trials in Phase 3/4

Results Transparency

0%

0 of 23 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
21(84.0%)
Phase 3
4(16.0%)
25Total
Phase 2(21)
Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials
NCT00622362Phase 2Terminated

Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract

Role: lead

NCT02340130Phase 2Completed

Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma

Role: lead

NCT01591343Phase 2Terminated

Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma

Role: lead

NCT01821716Phase 2Completed

Biological Standardization of Dermatophagoides Pteronyssinus Allergen Extract

Role: lead

NCT01739322Phase 2Completed

Biological Standardization of Platanus Acerifolia Allergen Extract

Role: lead

NCT00831025Phase 3Completed

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen

Role: lead

NCT02126111Phase 2Completed

Efficacy of a Depigmented Extract of Phleum in Local Allergic Rhinitis

Role: collaborator

NCT02512653Phase 2Completed

Biological Standarization of Cupressus Arizonica Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP)

Role: lead

NCT01984541Phase 2Completed

To Determine the Minimum Amount of Artemisia Vulgaris Allergen Extract Producing a Positive Skin Reaction.

Role: lead

NCT01984528Phase 2Completed

To Determine the Minimum Amount of Alternaria Alternata Allergen Extract Producing a Positive Skin Reaction.

Role: lead

NCT01675349Phase 2Completed

Biological Standardization of Chenopodium Album Allergen Extract

Role: lead

NCT01740024Phase 2Completed

Biological Potency of the Cat Epithelial Allergenic Extracts

Role: lead

NCT01734265Phase 2Completed

Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).

Role: lead

NCT00916422Phase 3Completed

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen

Role: lead

NCT00916760Phase 3Completed

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica

Role: lead

NCT01597752Phase 2Completed

Biological Standardization of Blomia Tropicalis Allergen Extract

Role: lead

NCT01394289Phase 2Completed

Biological Standardization of Lolium Perenne Allergen Extract

Role: lead

NCT01430117Phase 2Completed

Biological Standardization of Poa Pratensis Allergen Extract

Role: lead

NCT01408238Phase 2Completed

Biological Standardization of Secale Cereale Allergen Extract

Role: lead

NCT01407835Phase 2Completed

Biological Standardization of Dactylis Glomerata Allergen Extract

Role: lead